Nathan A. Pennell is running for the Board of Directors of ASCO

Nathan Pennell is a candidate for a position on the Board of Directors for ASCO.

The ASCO Nominating Committee has selected 13 distinguished members as candidates for leadership positions within the Society.

ASCO encourages all eligible members to vote for the new leaders of the Society.
Eligible members include those holding a Doctor of Medicine, Doctor of Osteopathy, Doctor of Philosophy, Doctor of Pharmacy, Doctor of Medical Science, Doctor of Nursing Science, Doctor of Nursing Practice, or an equivalent doctoral-level degree recognized by the Society and the Association, and who are in good standing as of October 14, 2024. Voting in the ASCO Election will earn eligible members a FASCO point.

The voting period ends on Tuesday, December 3, 2024, at 3:00 PM Eastern Standard Time. All ballots, whether submitted online or by paper, must be received by this deadline.

Nathan Pennell is nominated alongside Jason Westin, MD, MS, FACP.

Nathan A. Pennell, MD, PhD, FASCO is a Thoracic Medical Oncologist specialising in the treatment of thoracic malignancies, including lung cancer and mesothelioma.

The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes members for their volunteer engagement, and commitment to ASCO.

Dr. Nathan Pennell has been deeply involved with the American Society of Clinical Oncology (ASCO), contributing to a wide range of undertakings aimed at advancing cancer research.

His engagement with ASCO began in 2012, when he joined the Scientific Program Committee for Metastatic Lung Cancer and the Integrated Media and Technology Committee.

Over the years, he has held numerous editorial and leadership roles, including serving as Associate Editor for the ASCO Educational Book from 2012 to 2022 and consulting for the Journal of Oncology Practice on podcasts from 2015 to 2020.

Dr. Pennell has also been active in ASCO’s social media efforts, serving as a “Featured Voice” for lung cancer on Twitter from 2014 to 2020 and contributing as a blogger for ASCO Connection since 2015.

Dr. Pennell has also played an important role in ASCO’s educational and scientific programs. He was a member of the ASCO Cancer Education Committee for the Lung Cancer Track from 2016 to 2019 and has been involved in the ASCO/ASTRO/STS Multidisciplinary Thoracic Cancers Symposium, including serving as Co-Chair in 2019.

He also contributed as a Specialty Editor for the Clinical Cancer Advances Report on Lung Cancer in 2016, 2019, and 2020, and chaired the Road to Recovery Task Force on Cancer Research in 2020.

His leadership within ASCO was further recognized when he was elected to the Nominating Committee in 2021, and in 2022, he was named Editor in Chief of the ASCO Educational Book.

Dr. Pennell’s ongoing involvement with ASCO includes serving on the ASCO-Robert A. Winn Diversity in Clinical Trials Selection Working Group and as a Clinical Research Coach for awardees from 2023 to 2025.

Dr. Nathan A. Pennell is a graduate of the Leadership Development Program by ASCO and is also the Editor in Chief of the ASCO Educational Book.

Dr. Nathan Pennell is the Vice Chair of Clinical Research and Director of the Lung Cancer Medical Oncology Program at Cleveland Clinic Taussig Cancer Center.

Dr. Nathan Pennell has held numerous leadership positions and committee assignments at the Cleveland Clinic Foundation, contributing significantly to clinical care.

He began his leadership role in 2009 as a member of the Cancer Center Education Committee and Chair of the Review Committee in the Department of Nuclear Medicine.

In 2010, he was appointed Director of the Lung Cancer Medical Oncology Program, and in 2014, he became Co-Director of the Cleveland Clinic Lung Cancer Program. He also served on the Cancer Executive Committee and the VeloSano Grant Review Committee during this time.

From 2016 to 2019, Dr.Pennell was involved with the Inpatient EPIC Advisory Committee, followed by a role as Deputy Vice Chair for Clinical Research at the Taussig Cancer Institute (TCI) from 2018 to 2020.

He also served on the Enterprise Research Compliance Committee from 2018 to 2021. In 2020, he was promoted to Vice Chair of Clinical Research at Taussig Cancer Center, and in 2021, he became a member of the Enterprise Conflict of Interest Committee.

Dr. Pennell has been a part of 2012-14 Cancer Genome Atlas (TCGA) Mesothelioma Working Group and TCGA Mesothelioma Analysis Working Group at the National Cancer Institute.

Dr. Nathan Pennell has held numerous editorial roles across a wide range of oncology journals. Starting in 2006, he served as an ad hoc reviewer for journals such as Cancer, Clinical Cancer Research, and Journal of Thoracic Oncology. He

has served on the editorial boards of Translational Lung Cancer Research (2012–2019) and Frontiers in Thoracic Oncology (2013–2017).

Dr. Pennell also contributed as a Consultant Editor for the Journal of Oncology Practice from 2015 to 2020. His extensive review and editorial work expanded to prominent journals like Lancet Oncology, JAMA Oncology, and New England Journal of Medicine. Most recently, Dr. Pennell was named Editor in Chief of the ASCO Educational Book (2022–2027).

Education

Nathan Pennell completed his undergraduate studies in Biology at the University of North Carolina at Chapel Hill, earning a B.S. in 1993. He then pursued a Ph.D. in Neuroscience at the University of Florida, where he studied from 1993 to 1998.

Additionally, Dr.Pennell went on to complete his M.D. at the University of Florida College of Medicine, graduating with honors in 2002.

Dr. Pennell’s postgraduate training began with an internship in Medicine at Brigham and Women’s Hospital in Boston, where he trained from June 2002 to June 2003. He then completed his residency in Medicine at the same institution from July 2003 to June 2005.

After his residency, Dr. Pennell pursued a fellowship in Medical Oncology at Dana-Farber Partners CancerCare in Boston from 2005 to 2007.

During this time, he also participated in the Program in Clinical Effectiveness at the Harvard School of Public Health, focusing on epidemiology, statistics, and clinical trial design.

Awards and Honors

Dr. Nathan Pennell is a recipient of numerous awards and honors, some of which include:

• 2001: Alpha Omega Alpha – President, Florida Beta Chapter
• 2007: American Society of Clinical Oncology Foundation Merit Award
• 2011: Teacher of the Year – Cleveland Clinic Department of Solid Tumor Oncology
• 2013: Best Doctors in America
• 2013: Cleveland Magazine Best Doctors
• 2015: Castle Connolly Top Doctor
• 2015: Teacher of the Year – Cleveland Clinic Department of Hematology/Oncology
• 2016: Association Media and Publishing EXCEL Award, Best Blog Post
• 2018: Patient Educator of the Year – Global Resource for Advancing Cancer Education (GRACE)
• 2020: Fellow of the American Society of Clinical Oncology (FASCO)

Interviews with Nathan Pennell

Nathan Pennell, MD, PhD, Cleveland Clinic Hematology & Oncology (December 2021)

IASLC TTLC 2022 | Addressing unmet needs in patients with lung cancer – VJ Oncology (March 2022)

Dr. Pennell on Unique Treatment-Related Toxicities in Lung Cancer – OncLive (October 2016)

For more posts like this, visit oncodaily.com